233 related articles for article (PubMed ID: 19138420)
21. Current and potential treatments for primary biliary cholangitis.
Shah RA; Kowdley KV
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
[TBL] [Abstract][Full Text] [Related]
22. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
[TBL] [Abstract][Full Text] [Related]
24. [Determination of ursodeoxycholic acid and chenodeoxycholic acid in Chinese medicinal compound preparations by TLC-densitometry].
Zhang Z; Liao G; Song Y; Yin H
Zhongguo Zhong Yao Za Zhi; 1995 Mar; 20(3):162-4, 192. PubMed ID: 7646779
[TBL] [Abstract][Full Text] [Related]
25. AORTIC ANEURYSM, DISSECTION, AND RUPTURE IN SIX BILE-FARMED BEARS.
Bando MKH; Nelson OL; Webster N; Ramsay JD; Bacon HJ; Sellon R
J Zoo Wildl Med; 2018 Sep; 49(3):738-747. PubMed ID: 30212334
[TBL] [Abstract][Full Text] [Related]
26. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
27. [Chemical constituents of bear bile].
Luo Q; Chen Q; Wu Y; Jiang M; Chen Z; Zhang X; Chen H
Zhongguo Zhong Yao Za Zhi; 2010 Sep; 35(18):2416-9. PubMed ID: 21141490
[TBL] [Abstract][Full Text] [Related]
28. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.
Clayton PT; Mills KA; Johnson AW; Barabino A; Marazzi MG
Gut; 1996 Apr; 38(4):623-8. PubMed ID: 8707100
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. Effects on biliary lipid metabolism during weight maintenance and weight reduction.
Mazzella G; Bazzoli F; Festi D; Ronchi M; Aldini R; Roda A; Grigolo B; Simoni P; Villanova N; Roda E
Gastroenterology; 1991 Aug; 101(2):490-6. PubMed ID: 2065925
[TBL] [Abstract][Full Text] [Related]
30. [Research on artificial substitutes of rare and endangered animal medicinal materials and industrialization].
Wu XC; Jia XB; Ma WK; Wu Q; Wang L; Yang B; Feng L
Zhongguo Zhong Yao Za Zhi; 2022 Dec; 47(23):6278-6286. PubMed ID: 36604872
[TBL] [Abstract][Full Text] [Related]
31. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
33. Future development of global regulations of Chinese herbal products.
Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
[TBL] [Abstract][Full Text] [Related]
34. [Advances in studies on bear bile powder].
Zhou CF; Gao GJ; Liu Y
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(7):1252-8. PubMed ID: 26281541
[TBL] [Abstract][Full Text] [Related]
35. [Development history and prospect of Fel Ursi].
Li XY; Su FF; Jiang C; Zhang W; Wang F; Zhu Q; Yang G
Zhongguo Zhong Yao Za Zhi; 2022 Aug; 47(16):4284-4291. PubMed ID: 36046854
[TBL] [Abstract][Full Text] [Related]
36. Bile acid therapy versus placebo before and after extracorporeal shock wave lithotripsy of gallbladder stones. The East-Danish Gallstone Study Group.
Aliment Pharmacol Ther; 1996 Aug; 10(4):651-7. PubMed ID: 8853772
[TBL] [Abstract][Full Text] [Related]
37. [Study of characteristic ions in frequently-used traditional Chinese medicinal materials derived from animal bile and its application].
Shi Y; Xiong J; Wei F; Ma SC
Zhongguo Zhong Yao Za Zhi; 2018 Feb; 43(4):651-658. PubMed ID: 29600636
[TBL] [Abstract][Full Text] [Related]
38. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol.
Morton DH; Salen G; Batta AK; Shefer S; Tint GS; Belchis D; Shneider B; Puffenberger E; Bull L; Knisely AS
Gastroenterology; 2000 Jul; 119(1):188-95. PubMed ID: 10889168
[TBL] [Abstract][Full Text] [Related]
39. Distribution of cholesterol between vesicles and micelles in human gallbladder bile: influence of treatment with chenodeoxycholic acid and ursodeoxycholic acid.
Sahlin S; Thyberg P; Ahlberg J; Angelin B; Einarsson K
Hepatology; 1991 Jan; 13(1):104-10. PubMed ID: 1988332
[TBL] [Abstract][Full Text] [Related]
40. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.
Fischer S; Müller I; Zündt BZ; Jüngst C; Meyer G; Jüngst D
Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):305-11. PubMed ID: 15195895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
